Besides, the presence of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation predicts benefit from temozolomide-based chemotherapy in patients with IDH-wildtype glioma (Wick et al., 2012). Here, MGMT is linked to central nervous system cancer.